000126265 001__ 126265
000126265 005__ 20241125101148.0
000126265 0247_ $$2doi$$a10.1016/j.esmoop.2023.101155
000126265 0248_ $$2sideral$$a133665
000126265 037__ $$aART-2023-133665
000126265 041__ $$aeng
000126265 100__ $$aGrassi, L.
000126265 245__ $$aAnxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline
000126265 260__ $$c2023
000126265 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126265 5203_ $$aIntroduction: Anxiety and depression are the most common psychological symptoms in patients with cancer, irrespective of disease stage, primary cancer site and phase of treatment. Symptoms may range from nonpathological states, such as concerns, worry, sense of uncertainty, sadness and increased levels of hopelessness, to specific psychiatric syndromes (i.e. anxiety and depressive disorders). The latter are associated with significant distress and marked disability, poor quality of life (QoL), increased physical symptoms (e.g. pain or nausea), poor adherence to treatment, increased risk of suicide (in people with depression), poorer prognosis and higher mortality.1, 2, 3, 4 It is important for clinicians to understand the difference between nonpathological fluctuations in anxious or depressive states, which are not intense and are short-lived emotional responses to life challenges, and the more specific and impactful psychopathological conditions, such as anxiety and/or depressive disorders. There is a spectrum of highly comorbid syndromes which can be categorised by the criteria of the World Health Organization International Classification of Diseases (ICD), 11th edition (updated chapter on ‘Mental, behavioural or neurodevelopmental disorders’)5 and the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition-Text Revision (DSM-5-TR)...
000126265 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000126265 590__ $$a7.1$$b2023
000126265 592__ $$a2.498$$b2023
000126265 591__ $$aONCOLOGY$$b40 / 322 = 0.124$$c2023$$dQ1$$eT1
000126265 593__ $$aOncology$$c2023$$dQ1
000126265 593__ $$aCancer Research$$c2023$$dQ1
000126265 594__ $$a11.7$$b2023
000126265 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126265 700__ $$aCaruso, R.
000126265 700__ $$aRiba, M.B.
000126265 700__ $$aLloyd-Williams, M.
000126265 700__ $$aKissane, D.
000126265 700__ $$aRodin, G.
000126265 700__ $$aMcFarland, D.
000126265 700__ $$0(orcid)0000-0002-7197-0907$$aCampos-Ródenas, R.$$uUniversidad de Zaragoza
000126265 700__ $$aZachariae, R.
000126265 700__ $$aSantini, D.
000126265 700__ $$aRipamonti, C.I.
000126265 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000126265 773__ $$g8, 2 (2023), 101155 [14 pp.]$$pESMO open$$tESMO Open$$x2059-7029
000126265 8564_ $$s542783$$uhttps://zaguan.unizar.es/record/126265/files/texto_completo.pdf$$yVersión publicada
000126265 8564_ $$s2894351$$uhttps://zaguan.unizar.es/record/126265/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126265 909CO $$ooai:zaguan.unizar.es:126265$$particulos$$pdriver
000126265 951__ $$a2024-11-22-12:05:42
000126265 980__ $$aARTICLE